Skip to main content
. 2019 Sep 12;37(31):2857–2865. doi: 10.1200/JCO.19.00456

FIG 3.

FIG 3.

Circulating cell-free BRAFV600E kinetics according to time on vemurafenib and Langerhans cell histiocytosis risk organ extent (18 positive for risk organ involvement [black lines, blue diamonds]; four negative for risk organ involvement [red lines and squares]). The BRAFV600E allele load (expressed as the percentage of mutant alleles relative to the total number of alleles) is shown for each patient before vemurafenib onset (day 0), at weeks 6 to 8, and during months 3 to 6 and 9 to 12.